Trend Results : University of Texas MD Anderson


Related Searches

Blog Post Results (1-20 of 354)

FILTER RESULTS

PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers and BRCA Mutations

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) andShow More Summary

Novel Regulation of Gene Expression in Brain Tumors Identified

Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and spread, according to researchers at The University of Texas MD Anderson Cancer Center.

MD Anderson to present key drug study findings for multiple blood cancers at ASH annual meeting

(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology's (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.

MD Anderson to Present Key Drug Study Findings for Multiple Blood Cancers at ASH Annual Meeting

Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology's (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.

Researchers use fluorescent carbon nanotube probes to detect ovarian cancer

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have refined and, for the first time, run in vivo tests of a method that may allow nanotube-based probes to locate specific tumors in the body. Their ability to pinpoint tumors with submillimeter accuracy could eventually improve early detection and treatment of ovarian cancer.

MD Anderson Applauds Court-Ordered Corrective Statements From Tobacco Industry to Educate Public About Harms of Tobacco Use

As an institution dedicated to ending cancer, The University of Texas MD Anderson Cancer Center is committed to promoting cancer prevention and therefore supports the 'corrective statements' published by tobacco companies as a result of a 2006 judgment by U.S. Show More Summary

Six researchers from MD Anderson elected as AAAS Fellows

(University of Texas M. D. Anderson Cancer Center) In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS).

Six Researchers From MD Anderson Elected as AAAS Fellows

In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS).

Quality of Care for Older Texas Patients with Colon Cancer on the Rise, Still Room for Improvement

Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly among older Texas patients with colon cancer since 2001, while adherence to chemotherapy guidelines has remained largely unchanged. Show More Summary

Quality of care for older Texas patients with colon cancer on the rise, still room for improvement

(University of Texas M. D. Anderson Cancer Center) Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly among older Texas patients with colon cancer since 2001, while adherence to chemotherapy guidelines has remained largely unchanged. Show More Summary

Bacteria in the Gut Modulates Response to Immunotherapy in Melanoma

Bacteria that live in the human digestive tract can influence how cancer responds to immunotherapy, opening a new avenue for research to improve treatment, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the journal Science.

UC San Diego Health researchers help launch second pancreas cancer 'dream team'

(University of California - San Diego) Scientists and physicians at Moores Cancer Center at UC San Diego Health, in partnership with colleagues at MD Anderson Cancer Center in Texas, Johns Hopkins University in Maryland and elsewhere,...Show More Summary

Dream Team Aims to Intercept Pancreatic Cancer Before It Flourishes

Deeply entrenched and mature by the time it's found, pancreatic cancer is one of the hardest to defeat. A Dream Team assembled by Stand Up to Cancer and led by an investigator at The University of Texas MD Anderson Cancer Center will test new ways to find the disease in its emerging, more vulnerable phase in people who are at high risk for developing it.

Drug yields high response rates for lung cancer patients with harsh mutation

(University of Texas M. D. Anderson Cancer Center) A targeted therapy resurrected by the Moon Shots Program? at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries a highly treatment-resistant mutation.

Drug Yields High Response Rates for Lung Cancer Patients with Harsh Mutation

A targeted therapy resurrected by the Moon Shots Program(tm) at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries a highly treatment-resistant mutation.

MD Anderson Team Selected for National Push to Expand Immunotherapy

A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.

MD Anderson team selected for national push to expand immunotherapy

(University of Texas M. D. Anderson Cancer Center) A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.

MD Anderson and BridgeBio Pharma Launch Navire Pharma to Develop Targeted Therapy for Patients with Difficult-to-Treat Cancer

The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed at developing novel small-molecule inhibitors of a tyrosine-protein phosphatase called SHP2 for genetically driven and treatment-resistant cancer.

MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies

The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML).

Copyright © 2015 Regator, LLC